CD8A and neoplasm: Blocking CD47 and PD‐L1 by bispecific antibody could increase the antigen processing and presentation function of mregDCs and increase the frequency of stem‐like progenitor and effector CD8+ T‐cell subsets in the tumour, achieving an effective response to ICB therapy.87